- Home
- ODV vs AQST Comparison
ODV vs AQST Comparison
Compare ODV & AQST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ODV
- AQST
- Stock Information
- Founded
- ODV 2005
- AQST 2004
- Country
- ODV Canada
- AQST United States
- Employees
- ODV N/A
- AQST N/A
- Industry
- ODV Precious Metals
- AQST Biotechnology: Pharmaceutical Preparations
- Sector
- ODV Basic Materials
- AQST Health Care
- Exchange
- ODV Nasdaq
- AQST Nasdaq
- Market Cap
- ODV 338.9M
- AQST 390.4M
- IPO Year
- ODV N/A
- AQST 2018
- Fundamental
- Price
- ODV $2.96
- AQST $5.42
- Analyst Decision
- ODV
- AQST Strong Buy
- Analyst Count
- ODV 0
- AQST 6
- Target Price
- ODV N/A
- AQST $10.67
- AVG Volume (30 Days)
- ODV 1.0M
- AQST 2.5M
- Earning Date
- ODV 08-12-2025
- AQST 11-03-2025
- Dividend Yield
- ODV N/A
- AQST N/A
- EPS Growth
- ODV N/A
- AQST N/A
- EPS
- ODV N/A
- AQST N/A
- Revenue
- ODV $5,147,156.00
- AQST $44,132,000.00
- Revenue This Year
- ODV $381.12
- AQST N/A
- Revenue Next Year
- ODV $256.81
- AQST $38.71
- P/E Ratio
- ODV N/A
- AQST N/A
- Revenue Growth
- ODV N/A
- AQST N/A
- 52 Week Low
- ODV $1.16
- AQST $2.12
- 52 Week High
- ODV $3.03
- AQST $5.80
- Technical
- Relative Strength Index (RSI)
- ODV 66.51
- AQST 80.05
- Support Level
- ODV $2.73
- AQST $3.73
- Resistance Level
- ODV $2.89
- AQST $4.00
- Average True Range (ATR)
- ODV 0.15
- AQST 0.26
- MACD
- ODV 0.02
- AQST 0.13
- Stochastic Oscillator
- ODV 88.98
- AQST 96.57
About ODV Osisko Development Corp.
Osisko Development Corp is a mineral exploration and development company engaged in the acquisition, exploration, and development of precious metals resource properties in North America. The company is focused on exploring and developing its mining assets, including the Cariboo Gold Project in British Columbia, the San Antonio gold project in Mexico, and the Trixie test mine in the USA. The Company manages its business through the exploration, evaluation, and development activities of its projects.
About AQST Aquestive Therapeutics Inc.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.